Research programme: beta lactamase inhibitors - LigaChem Biosciences/Geom Therapeutics
Alternative Names: GT-055; LCB18 0055Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator LegoChem Biosciences
- Developer Geom Therapeutics; LigaChem Biosciences
- Class Antibacterials; Small molecules
- Mechanism of Action Beta lactamase inhibitors; Penicillin-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 13 Apr 2019 Antimicrobial data from preclinical trial in Gram-negative infections presented at 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)
- 20 Jul 2018 Antimicrobial data from preclinical trial in Gram-negative infections presented at ASM Microbe 2018 (ASMM-2018)